5.89  0.44 (8.07%)		04-20 13:37
Open: 5.52 High: 6.1 Volume: 393,691		Pre. Close: 5.45 Low: 5.52 Market Cap: 33(M)

Short term
Mid term
Targets	6-month :	10.84	1-year :	13.88
Resists	First :	9.28	Second :	11.89
Pivot price	5.77
Supports	First :	5.07	Second :	4.22
MAs	MA(5) :	5.43	MA(20) :	5.96
	MA(100) :	5.67	MA(250) :	4.74
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	27	D(3) :	15.2
RSI	RSI(14): 46.5
52-week	High :	11.89	Low :	3.2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CING ] has closed below upper band by 40.5%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.61 - 5.64	5.64 - 5.67
Low:	5.24 - 5.27	5.27 - 5.29
Close:	5.4 - 5.45	5.45 - 5.5

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Tue, 14 Apr 2026
Cingulate Inc. (NASDAQ: CING) registers 4.21M resale shares; Falcon Creek holds 3.86M - Stock Titan

Mon, 06 Apr 2026
Cingulate says its ADHD drug faces manufacturing review, not safety issues - Stock Titan

Mon, 06 Apr 2026
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 - Yahoo Finance

Thu, 02 Apr 2026
CING SEC Filings - Cingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Wed, 25 Mar 2026
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan

Fri, 20 Mar 2026
CING: Laying the Foundation for 1H:27 Launch - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	11 (M)
Held by Insiders	35.4 (%)
Held by Institutions	4.6 (%)
Shares Short	1,080 (K)
Shares Short P.Month	464 (K)

EPS	-4.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-83.3 %
Return on Equity (ttm)	-450.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.8
Sales Per Share	0
EBITDA (p.s.)	-1.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-17 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-1.33
PEG Ratio	0
Price to Book value	16.84
Price to Sales	0
Price to Cash Flow	-4.19

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.